NO20091605L - Pyridinonforbindelser - Google Patents

Pyridinonforbindelser

Info

Publication number
NO20091605L
NO20091605L NO20091605A NO20091605A NO20091605L NO 20091605 L NO20091605 L NO 20091605L NO 20091605 A NO20091605 A NO 20091605A NO 20091605 A NO20091605 A NO 20091605A NO 20091605 L NO20091605 L NO 20091605L
Authority
NO
Norway
Prior art keywords
compound
pyridinonforbindelser
administering
cancer
methods
Prior art date
Application number
NO20091605A
Other languages
English (en)
Other versions
NO342395B1 (no
Inventor
Robert M Borzilleri
Gretchen M Schroeder
Zhen-Wei Cai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20091605L publication Critical patent/NO20091605L/no
Publication of NO342395B1 publication Critical patent/NO342395B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen angår pyridinonforbindelser anvendelige for å modulere Met kinase, som har følgende struktur: og er videre rettet mot farmasøytiske preparater omfattende forbindelsen; og metoder for behandling av proliferative sykdommer, så som kreft ved administrering av denne forbindelsen.
NO20091605A 2006-11-08 2009-04-22 Pyridinonforbindelser, farmasøytiske preparater omfattende slike forbindelser samt anvendelse av slike forbindelser og preparater for behandling av kreft NO342395B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85754006P 2006-11-08 2006-11-08
PCT/US2007/084047 WO2008058229A1 (en) 2006-11-08 2007-11-08 Pyridinone compounds

Publications (2)

Publication Number Publication Date
NO20091605L true NO20091605L (no) 2009-05-27
NO342395B1 NO342395B1 (no) 2018-05-14

Family

ID=39048786

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091605A NO342395B1 (no) 2006-11-08 2009-04-22 Pyridinonforbindelser, farmasøytiske preparater omfattende slike forbindelser samt anvendelse av slike forbindelser og preparater for behandling av kreft

Country Status (21)

Country Link
US (2) US7851489B2 (no)
EP (1) EP2089364B1 (no)
JP (1) JP5276005B2 (no)
KR (1) KR101390076B1 (no)
CN (1) CN101535264B (no)
AR (1) AR063628A1 (no)
AU (1) AU2007317296B2 (no)
CA (1) CA2669266C (no)
CL (1) CL2007003226A1 (no)
DK (1) DK2089364T3 (no)
ES (1) ES2424851T3 (no)
HK (1) HK1131608A1 (no)
HR (1) HRP20130626T1 (no)
MX (1) MX2009004699A (no)
NO (1) NO342395B1 (no)
PE (1) PE20081490A1 (no)
PL (1) PL2089364T3 (no)
PT (1) PT2089364E (no)
SI (1) SI2089364T1 (no)
TW (1) TWI409259B (no)
WO (1) WO2008058229A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101608096B1 (ko) * 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암을 위한 그의 용도
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AU2011248441A1 (en) 2010-04-29 2012-12-20 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
PT2563763E (pt) * 2010-04-30 2015-03-31 Bristol Myers Squibb Co Composições farmacêuticas que compreendem n-(4-(2-amino-3-cloropiridin-4-iloxi)-3-fluorofenil)-4- etoxi-l-(4-fluorofenil)-2-oxo-1,2-dihidropiridina-3- carboxamida
CN102241625B (zh) * 2010-05-13 2014-10-29 中南大学 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途
CN102070518B (zh) * 2011-01-24 2012-05-02 江苏先声药物研究有限公司 取代吡啶及氮杂吲哚衍生物的合成
SG194219A1 (en) 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
MX2014006126A (es) 2011-11-22 2015-03-19 Deciphera Pharmaceuticals Llc Amidas de piridona y analogos que exhiben actividades anticancerigenas y antiproliferativas.
WO2014022117A1 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CA3005727A1 (en) 2015-11-19 2017-05-26 Incyte Corporation Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators
PE20230731A1 (es) 2015-12-22 2023-05-03 Incyte Corp Compuestos heterociclicos como inmunomoduladores
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
PE20190731A1 (es) 2016-06-20 2019-05-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
ES2930092T3 (es) * 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
CA3044366A1 (en) * 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MY197635A (en) 2016-12-22 2023-06-29 Incyte Corp Benzooxazole derivatives as immunomodulators
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
TW201834649A (zh) 2017-03-02 2018-10-01 新加坡商亞獅康私人有限公司 癌症療法
CN108623568B (zh) * 2017-03-21 2022-04-19 南京汇诚制药有限公司 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2019083455A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS
WO2019083458A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA
WO2019083457A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY
WO2019083456A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS
EP3719012B1 (en) * 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
CN111295386B (zh) 2018-03-08 2022-09-06 伟迈可生物有限公司 噻吩并吡啶衍生物及含有该衍生物的药物组合物
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
JP2022504201A (ja) 2018-10-09 2022-01-13 アスラン ファーマシューティカルズ ピーティーイー リミテッド バリチニブのマロン酸塩
EP3867229A4 (en) * 2018-10-19 2022-07-27 The University Of British Columbia TOPOISOMERASE II CATALYTIC INHIBITOR COMPOUND THERAPEUTIC AGENTS FOR CANCER TREATMENT, METHODS AND USES
US20220119425A1 (en) * 2019-01-15 2022-04-21 The Translational Genomics Research Institute Phosphonate conjugates and uses thereof
JP2022543250A (ja) 2019-08-02 2022-10-11 ウェルマーカー・バイオ・カンパニー・リミテッド オキソ－ピリジン縮合環誘導体、およびそれを含む医薬組成物
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
EP3819300A4 (en) 2019-09-06 2021-11-24 Wellmarker Bio Co., Ltd. THERAPEUTIC COMPOSITION BASED ON BIOMARKERS
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
CN115003307A (zh) 2020-02-06 2022-09-02 伟迈可生物有限公司 用于预防或治疗与kras突变相关的癌症的药物组合物
JP2023516381A (ja) 2020-03-03 2023-04-19 ウェルマーカー・バイオ・カンパニー・リミテッド Ｋｒａｓ変異および活性化ｒｏｎが存在する癌の予防または治療のための医薬組成物
KR20210142555A (ko) 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 췌장암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
KR20210142554A (ko) 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 비소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
WO2021235811A1 (ko) 2020-05-18 2021-11-25 웰마커바이오 주식회사 Ron 돌연변이와 관련된 소세포 폐암 예방 또는 치료용 약학 조성물 및 이를 이용한 방법
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN117355533A (zh) * 2021-06-22 2024-01-05 株式会社Lg化学 作为蛋白激酶抑制剂的新型化合物
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430885A3 (en) 1989-12-01 1991-11-06 Ciba-Geigy Ag Anthelmintical compounds
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
JP2002518368A (ja) 1998-06-17 2002-06-25 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類
AU780698B2 (en) 1999-07-20 2005-04-14 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
SE0102384D0 (sv) 2001-07-03 2001-07-03 Pharmacia Ab New compounds
WO2003045921A1 (en) 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP4829506B2 (ja) 2004-02-17 2011-12-07 石原産業株式会社 チオアミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
WO2005113494A2 (en) 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
KR20090096423A (ko) 2009-09-10
NO342395B1 (no) 2018-05-14
HK1131608A1 (en) 2010-01-29
ES2424851T3 (es) 2013-10-09
EP2089364B1 (en) 2013-06-12
AR063628A1 (es) 2009-02-04
CN101535264A (zh) 2009-09-16
WO2008058229A1 (en) 2008-05-15
US8536200B2 (en) 2013-09-17
JP2010509362A (ja) 2010-03-25
EP2089364A1 (en) 2009-08-19
HRP20130626T1 (en) 2013-08-31
KR101390076B1 (ko) 2014-04-29
JP5276005B2 (ja) 2013-08-28
CA2669266C (en) 2014-04-29
PL2089364T3 (pl) 2013-11-29
CA2669266A1 (en) 2008-05-15
US20110052583A1 (en) 2011-03-03
PT2089364E (pt) 2013-08-26
SI2089364T1 (sl) 2013-10-30
TWI409259B (zh) 2013-09-21
US20080114033A1 (en) 2008-05-15
AU2007317296B2 (en) 2012-07-05
CN101535264B (zh) 2012-11-28
MX2009004699A (es) 2009-05-15
US7851489B2 (en) 2010-12-14
CL2007003226A1 (es) 2008-02-08
TW200829564A (en) 2008-07-16
DK2089364T3 (da) 2013-09-02
AU2007317296A1 (en) 2008-05-15
PE20081490A1 (es) 2008-10-30

Similar Documents

Publication Publication Date Title
NO20091605L (no) Pyridinonforbindelser
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
WO2008033562A3 (en) Kinase inhibitor compounds
UA107783C2 (en) Isoindoline compounds for use in treating cancer
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
NO20080150L (no) Inhibitorer av AKT-aktivitet
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
WO2010108074A3 (en) Inhibitors of pi3 kinase
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
NO20084435L (no) C-MET proteinkinaseinhibitorer
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
NO20081454L (no) Met-kinaseinhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
ATE522518T1 (de) Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus